Global Drug Facility seeks expressions of interest from anti-TB drug manufacturers
The Global Drug facility (GDF) has issued two invitations to manufacturers of anti-TB medicines to submit an expression of interest for product evaluation by an expert review panel (ERP).
The first, issued jointly with the Global Fund To Fight AIDS, Tuberculosis and Malaria, invites submissions of product dossiers on first-line drugs for which there are less than three products of the same formulations that are WHO-Prequalified, SRA-approved and available worldwide.
The second invitation is to manufacturers of second- and third-line anti-TB drugs for which there less than three products of the same formulations that are WHO Prequalified, SRA-approved and available in the global market.
The deadline for submission for expressions of interest in both categories is 15 September 2010, 17:00 Geneva time.